Leland Gershell

Stock Analyst at Oppenheimer

(0)
# 4174
Out of 5,311 analysts
149
Total ratings
34.23%
Success rate
-11.34%
Average return
46 Stocks
Name Action Price Target Current % Upside Ratings Updated
QNCX Quince Therapeutics
Initiates Coverage On: Outperform
10
0.99 910.1% 1 Mar 24, 2025
TRVI Trevi Therapeutics
Maintains: Outperform
12 20
5.03 297.61% 3 Mar 11, 2025
ARGX argenx
Maintains: Outperform
675 704
549.32 28.16% 6 Feb 28, 2025
BMRN Biomarin Pharmaceutical
Upgrades: Outperform
98
56.38 73.82% 3 Feb 24, 2025
RYTM Rhythm Pharmaceuticals
Initiates Coverage On: Outperform
76
57.11 33.08% 1 Dec 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
190 180
141.09 27.58% 10 Nov 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
48 52
15.58 233.76% 2 Nov 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
135 147
100.86 45.75% 2 Nov 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
5 5
0.51 880.39% 8 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 2 Nov 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
65 73
62.29 17.19% 8 Oct 28, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
40 40
9.38 326.44% 9 Oct 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
47 53
15.21 248.45% 3 Oct 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Perform
n/a
n/a n/a 1 Oct 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
15 43
9.12 371.49% 4 Sep 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30 30
4 650% 2 Sep 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
12 12
1.18 916.95% 2 Sep 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
150 25
0.73 3324.66% 9 Sep 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
31 28
11.44 144.76% 5 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 25
3.73 570.24% 3 Aug 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
74 73
26.7 173.41% 7 Aug 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 13
n/a n/a 5 Aug 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
14 20
1.45 1279.31% 5 Jul 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
29 29
21.77 33.21% 3 Jun 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
35
4.75 636.84% 2 Apr 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
10 10
0.69 1349.28% 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
5
3.98 25.63% 1 Mar 28, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
23 20
0.96 1983.33% 3 Nov 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 7 Oct 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 13
0.71 1730.99% 3 Apr 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
5 4
0.2 1900% 1 Mar 24, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 1 Oct 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Perform
n/a
n/a n/a 2 Aug 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
140
n/a n/a 1 Mar 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
36
n/a n/a 4 Dec 22, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
42
n/a n/a 1 Dec 9, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
12
n/a n/a 1 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
360000
n/a n/a 1 Jun 4, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Perform
n/a
n/a n/a 2 Mar 15, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Perform
n/a
n/a n/a 2 Nov 25, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
50
2.03 2363.05% 1 Oct 23, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
4620 1470
n/a n/a 2 Sep 25, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
225
n/a n/a 1 Aug 25, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
112 115
n/a n/a 2 May 12, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Perform
16 17
n/a n/a 2 May 5, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Perform
n/a
n/a n/a 4 Mar 31, 2020